|
gptkbp:instanceOf
|
gptkb:gene
|
|
gptkbp:alsoKnownAs
|
gptkb:MEK1
gptkb:MAPKK1
|
|
gptkbp:associatedWith
|
gptkb:cancer
gptkb:Cardiofaciocutaneous_syndrome
gptkb:Noonan_syndrome
|
|
gptkbp:biologicalProcess
|
signal transduction
protein serine/threonine kinase activity
|
|
gptkbp:cellularComponent
|
gptkb:nucleus
gptkb:cytoplasm
|
|
gptkbp:discoveredBy
|
1992
|
|
gptkbp:encodes
|
gptkb:Mitogen-activated_protein_kinase_kinase_1
|
|
gptkbp:Entrez_Gene_ID
|
5604
ENSG00000169032
|
|
gptkbp:expressedIn
|
many tissues
|
|
gptkbp:function
|
phosphorylates and activates MAP kinases (ERK1/2)
|
|
gptkbp:geneType
|
protein coding
|
|
gptkbp:HGNC_ID
|
6840
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MAP2K1
|
|
gptkbp:inhibitedBy
|
gptkb:Selumetinib
gptkb:Cobimetinib
gptkb:Trametinib
|
|
gptkbp:interactsWith
|
gptkb:BRAF
gptkb:RAF1
MAPK1 (ERK2)
MAPK3 (ERK1)
|
|
gptkbp:length
|
393 amino acids
|
|
gptkbp:locatedOnChromosome
|
gptkb:chromosome_15
15q22.31
|
|
gptkbp:mutationAssociatedWith
|
mutations associated with drug resistance in cancer
gain-of-function mutations cause developmental syndromes
|
|
gptkbp:OMIM
|
176872
|
|
gptkbp:organism
|
gptkb:Homo_sapiens
|
|
gptkbp:orthologInMouse
|
gptkb:Map2k1
|
|
gptkbp:pathway
|
gptkb:MAPK/ERK_pathway
|
|
gptkbp:PDB
|
gptkb:4AN2
3EQF
4U7Z
|
|
gptkbp:phosphorylates
|
Ser218
Ser222
|
|
gptkbp:proteinFamily
|
gptkb:MAP_kinase_kinase_family
protein kinase domain
N-terminal regulatory domain
|
|
gptkbp:regulates
|
apoptosis
cell differentiation
cell proliferation
cell survival
activated by phosphorylation by RAF kinases
|
|
gptkbp:UniProtID
|
Q02750
|
|
gptkbp:bfsParent
|
gptkb:B-RAF1
gptkb:MEK1
gptkb:serine/threonine-protein_kinase_B-raf
gptkb:HRAS1
gptkb:MAPK_signaling_pathway
gptkb:Noonan_syndrome
gptkb:3265_(HRAS)
gptkb:KEGG:_hsa04014
gptkb:P01112_(HRAS)
|
|
gptkbp:bfsLayer
|
6
|